FYIAcadia Pharmaceuticals to Present Late-Breaking Data at the...

FYI
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American
Academy of Neurology Annual Meeting (AAN)

-- Rett syndrome research to include oral presentation of Phase 3 Lavender
trial and poster presentation highlighting the patient journey and clinical
burden of the disease

-- E-poster presentation evaluating maintenance of efficacy and safety of
pimavanserin among patients with Parkinson’s disease dementia with psychosis

Business Wire

SAN DIEGO -- March 22, 2022

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking
oral presentation on the efficacy and safety data from the Phase 3 Lavender
study of trofinetide, an investigational treatment for Rett syndrome (RTT),
will be presented at the 2022 American Academy of Neurology Annual Meeting
(AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.

“We look forward to the upcoming presentation of the Phase 3 Lavender results
at this year’s AAN and the opportunity to educate neurologists on the critical
unmet need that exists for patients and their caregivers living with this rare
and serious neurological disease,” said Kathie Bishop, Ph.D., Acadia’s Senior
Vice President, Chief Scientific Officer and Head of Rare Disease.

AAN Accepted Presentations and Posters:

Emerging Science (Late-Breaker):

* Oral Presentation: Efficacy and safety of trofinetide for the treatment of
Rett syndrome: results from the pivotal phase 3 Lavender study.
Tuesday, April 5, from 9:15 a.m. - 11:30 a.m.

Posters:

* Poster # 001: Patient journey and clinical burden of Rett syndrome in the
United States: research study including nearly 6,000 girls provides an
overview of the patient journey and clinical burden of RTT with respect to
baseline characteristics, clinical manifestations and treatment patterns
among female individuals in the US.
Tuesday, April 5, from11:45 a.m. - 12:45 p.m.